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Background/Objectives: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in older people but
currently no speciﬁc drugs are available for its treatment. Omega-3 polyunsaturated fatty acids (n-
3PUFA), known for their lipid-lowering, anti-inﬂammatory and anti-hypertensive properties, may have
therapeutic potential for the management of NAFLD. The aim of this study was to determine whether n-
3PUFA levels are associated with the prevalence of NAFLD in older adults.
Methods: A cross-sectional sample of older adults aged 65e95 years (n ¼ 620) from the Retirement
Health and Lifestyle Study (RHLS) was analysed. Fatty Liver Index (FLI) scores, used as an indicator of
NAFLD risk, were calculated using a validated algorithm that incorporates body mass index, waist
circumference, plasma triglycerides and g-glutamyl transferase. Omega-3 index scores (O3I, %eicosa-
pentaenoic acid plus %docosahexaenoic acid) were determined by analysing the fatty acid composition of
erythrocyte membranes by gas chromatography.
Results: Following application of exclusion criteria, 475 participants were included in the analysis (age
77.9 ± 7.0 years; 60.4% females). Of these, 216 participants had FLI scores (60) suggestive of NAFLD (age
77.0 ± 6.6 years; 49.1% females). O3I was signiﬁcantly lower in participants with NAFLD compared to
those without NAFLD (p < 0.01). A signiﬁcant inverse relationship was found between O3I and FLI
(r ¼ 0.165; p < 0.001). This relationship was gender speciﬁc with women, but not men, showing a
signiﬁcant association (r ¼ 0.206; p < 0.001).
Conclusions: The current study demonstrated a sex-dependent inverse relationship between erythrocyte
n-3PUFA concentrations and NAFLD in older adults. The ﬁnding supports the proposal for sex-stratiﬁed
n-3PUFA intervention trials in this high-risk age group.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-alcoholic fatty liver disease (NAFLD), deﬁned as the accu-
mulation of fat (>5%) in the hepatocytes of the liver [1e3], repre-
sents a broad spectrum of conditions ranging from steatosis to the
more severe non-alcoholic steatohepatitis (NASH) [3]. If left un-
detected or untreated, NAFLD can progress to ﬁbrosis, cirrhosis and
potentially liver failure [4]. In 2012, NAFLD was reported to be the
most prevalent of all the liver diseases in Australia and wasing, University of Newcastle,
M.L. Garg).
Inc. This is an open access article uestimated to affect 5.5 million Australians including approximately
40% of adults aged 50 years or older [5]. By the year 2030, the
number of Australians diagnosed with NAFLD is expected to exceed
7 million [5]. Furthermore, it has also been reported that NAFLD is
becoming more prevalent in the older population (>60 years) [6]
with post-menopausal women more likely to develop NAFLD
than men of the same age [6].
Recent studies suggest that NAFLD is the hepatic expression of
the metabolic syndrome with risk factors including insulin resis-
tance, obesity, hyperlipidaemia, and hypertension [7e10]. Two
stages have been proposed in the pathogenesis of the disease
[1,6,11,12]. The ﬁrst stage is the accumulation of free fatty acids
(FFA) and triglycerides (TG) in the liver due to excessive storage ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sugar intake or de-novo lipogenesis [13]. The second is mitochon-
drial dysfunction, oxidative stress and inﬂammation in addition to
steatosis and results from the increase in serum FFA and serum TG
[11]. However, not all patients with steatosis progress to NASH,
indicating that additional stages may be involved in disease pro-
gression [14,15].
Currently, there is no speciﬁc treatment for NAFLD. Manage-
ment options include lifestyle modiﬁcations (dietary energy re-
strictions, increased physical activity and weight loss) [16,17] and
pharmacological agents (anti-hypertensive, lipid lowering, insulin
sensitizing and weight loss medications) [14,15]. However, these
options are complicated by the need for long-term compliance and
concerns regarding the safety of medications such as insulin-
sensitizing agents [14]. Development of safe and efﬁcacious treat-
ments and prevention strategies is therefore highly desirable [15].
A promising therapy for the management and treatment of
NAFLD is increasing omega-3 polyunsaturated fatty acids intake (n-
3PUFA) [3]. N-3PUFA are recognised to have lipid-lowering, anti-
inﬂammatory [18] and anti-hypertensive properties, although the
mechanisms underlying these effects have not been fully eluci-
dated. Evidence suggests that eicosapentaenoic (20:5n-3, EPA) and
docosahexaenoic (22:6n-3, DHA) acids may reduce serum and he-
patic TG, and decrease the production of the pro-inﬂammatory
cytokines tumour necrosis factor alpha (TNFa) and interleukin-6
(IL-6) [19]. Other studies have also shown that n-3PUFA compete
with omega-6 fatty acids for metabolism, thereby promoting the
production of less-inﬂammatory eicosanoids (thromboxane and
prostaglandins of the 3-series), and reducing the formation of pro-
inﬂammatory 2-series eicosanoids [20]. In addition, EPA and DHA
may serve as precursors for the synthesis of resolvins and pro-
tectins, promoting resolution of the inﬂammatory component of
NAFLD [17]. Observational and interventional studies have reported
an inverse association between n-3PUFA and NAFLD. Previous
studies have been conducted in younger populations using objec-
tive measures of NAFLD [3]. Further work is needed to establish the
relationship between long-term n-3PUFA status and NAFLD.
Typically, imaging procedures, such as ultrasound, computer-
ized tomography scans and magnetic resonance imaging, have
been used to diagnose fatty liver disease. However, an alternative
validated non-invasive method for diagnosing NAFLD is the Fatty
Liver Index (FLI) [21e23]. This index assesses risk of fatty liver
disease using an algorithm based on four criteria; body mass index
(BMI), TG, waist circumference and g-glutamyl transferase (GGT)
[18]. Our study used the FLI to assess NAFLD risk in a group of adults
aged 65 years or older. While previous studies have been conducted
with younger populations using non-FLI diagnostic tools [19,24,25],
the current studywas the ﬁrst to examine the potential relationship
between n-3PUFA status and NAFLD in older Australians. The
omega-3 index (O3I), the sum of %EPA and %DHA in erythrocyte
membranes [26], was used as a validated measure of long-term n-
3PUFA status.
2. Subjects and methods
2.1. Subjects and study design
A cross-sectional analysis was conducted using data collected
for the Retirement Health and Lifestyle Study (RHLS) between 2010
and 2012. The RHLS eligibility criteria included: 65 years of age,
living independently in a retirement or community dwelling for 12
months or more and living within the Gosford/Wyong Local Gov-
ernment Areas. People were ineligible for the RHLS if: they were
not independently living or were residing in a communal setting
other than a retirement village, their listed address was not theirprimary residence, or another member of their household was
taking part in the study. People with language and/or other
communicative difﬁculties, or who were cognitively impaired and/
or unable to provide informed consent, were also excluded. Par-
ticipants were included in the current analyses if they had eryth-
rocyte samples available for fatty acid analysis, valid height, weight,
waist circumference, GGT and TG measures, and their liver disease
status and daily alcohol intake could be determined. Participants
were excluded if they reported liver disease other than fatty liver
disease, or an alcohol intake exceeding 20.5 g per day.
All RHLS participants (n ¼ 831) took part in an interviewer-
administered questionnaire (IAQ) that collected information
relating to demographics and health status including lifestyle fac-
tors and physical activity [27]. A subset of participants also took
part in a clinical assessment that included measurement of
anthropomorphic characteristics and sitting blood pressures. The
majority of clinic participants provided a fasted blood sample and
completed a self-administered food frequency questionnaire (FFQ)
[28] as part of a physical activity questionnaire [29e32]. Erythro-
cyte samples were available for determination of O3I for 620
participants.
The study protocols were approved by the University of New-
castle Human Research Ethics Committee (Reference No. H-2008-
0431) and the Northern Sydney Central Coast Health Human
Research Ethics Committee (Reference No. 1001-031 M) and all
participants provided written informed consent.
2.2. Anthropometric measures
Anthropometric measurements were taken by trained research
ofﬁcers using standardised protocols outlined by the World Health
Organisation [33]. Participants were weighed in light clothing and
without shoes to the nearest 100 g using standardised digital scales
(Tanita HD-316 scales, Tanita Corporation, Tokyo, Japan; or Wed-
derburn UWPM150 Digital Platform Scales, Wedderburn Scales,
Australia). Height was measured without shoes to the nearest
0.1 cm using a portable stadiometer (Design No. 1013522, Surgical
and Medical Products, Seven Hills, NSW, Australia). Waist circum-
ference was measured between the lower costal margin and the
iliac crest using a non-elastic ﬂexible measuring tape
(150 cm  12 mm, Sullivans International), to the nearest 0.1 cm.
Subjects were asked to remove any heavy clothing and belts, and
measurements were conducted either on bare skin or over loose
ﬁtting clothing. Hip measurements, to the nearest 0.1 cm, were
taken from the greatest posterior protuberance of the buttocks
using a non-elastic ﬂexible measuring tape. All anthropometric
measurements were taken twice. If themeasurements disagreed by
more than set tolerance limits (weight, 800 g; height, 1 cm; waist
circumference, 2 cm; and hip circumference, 2 cm) a third measure
was taken. Each measure was presented as the mean of the two
observations or the mean of the two closest measurements if a
third was taken. Height and weight measurements were used to
calculate BMI (kg/m2).
2.3. Sitting blood pressure and pulse measures
Sitting blood pressure measurements were conducted by
trained research ofﬁcers following protocols outlined by the Na-
tional Heart Foundation of Australia [34]. Participants were asked
to avoid strenuous exercise for 24 h prior to measurement, fast
overnight and abstain from smoking on the morning of measure-
ment. Two measurements were taken at 1 min intervals using an
Omron 1A2 digital automatic blood pressure monitor (Omron,
Australia) with participants seated in a chair, feet ﬂat on the ground
and legs uncrossed. If the two readings differed by more than
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respectively, up to two further measurements were taken until
consecutive readings did not vary by greater than these amounts.
2.4. Biochemical analyses
Blood samples were collected by trained phlebotomists and
were analysed by Hunter Area Pathology Service (HAPS). Routine
biochemical analyses included blood lipids (total cholesterol (TC),
LDL-cholesterol, HDL-cholesterol, TG), diabetes markers (fasting
blood glucose, insulin), inﬂammatory marker (C-reactive protein
(CRP)), and liver function tests (total bilirubin, GGT, alkaline phos-
phatase (ALP), alanine transaminase (ALT), and aspartate amino-
transferase (AST)).
For erythrocyte membrane fatty acid composition determina-
tion, blood samples were centrifuged at 3000g for 10 min to
separate the plasma and erythrocyte fractions. The fatty acid
composition of the erythrocyte membranes was then determined
via direct trans-esteriﬁcation of the washed erythrocyte fractions
[35], followed by gas chromatographic analysis [36]. A known fatty
acid mixturewas used to identify peaks according to retention time
and their concentration was determined using a Hewlett Packard
6890 Series GC with Chemstation Version A. 04.02.
2.5. Dietary assessments
Dietary intakes of energy, protein, carbohydrate, fat and alcohol
were determined using a 41-question self-administered food fre-
quency questionnaire (FFQ) that was adapted from the validated
CSIRO FFQ [28], and modiﬁed for self-administration. Nutrient in-
takes were analysed in FoodWorks Professional Edition Version
6.0.2562 (Xyris Software, Brisbane, Queensland, Australia).
Australian databases used included Abbott products, AusFoods
(Brands) 2006, AusNut (All Foods) 2007, Australia (Fatty Acids), and
the New Zealand vitamin and mineral supplements 1999.
2.6. Fatty liver index
FLI was calculated using an algorithm based on four markers:
BMI, TG, GGT, and waist circumference [21]. Evidence shows
that this index detects fatty liver with an accuracy of 0.84 [21].
The index is scored 0e100; a score of less than 30 rules
out fatty liver whilst a score of 60 or over indicates fatty liver
[18e20]. The algorithm used to calculate the FLI was:
[e0.953  loge(triglycerides) þ 0.139  BMI þ 0.718  loge(GGT) þ 0.053  waist
circumference15.745]/[1 þ e0.953  loge(triglycerides) þ 0.139 
BMI þ 0.718  loge(GGT) þ 0.053  waist circumference15.745]  100 [21].
2.7. Statistical analysis
Data was analysed using Statistical Package for the Social Sci-
ences (SPSS; Release 22.0, Chicago, IL: SPSS Inc.). Data was reported
as mean ± standard deviation or frequency, as appropriate. Groups
were compared using chi-square analyses and independent sample
two-tailed t-tests. Differences in the proportion of people with
NAFLD across O3I quartiles were reported as odds ratios (OR, 95%
CI) using the lowest quartile as the reference. Bivariate and multi-
variate relationships were analysed using Pearson product-
moment correlation and hierarchical regression analyses. Vari-
ables were entered into the hierarchical regression in three blocks.
Demographic variables (age and gender) were entered into the
regression analysis at block 1. Clinically relevant biochemical vari-
ables that correlated with FLI (HDL, CRP, fasting glucose and insu-
lin) were entered at block 2 and the test variable, O3I, was entered
at block 3. Pair-wise exclusion for missing data was employed in allregression analyses. Statistical signiﬁcance was set at p < 0.05.
3. Results
Following application of the exclusion criteria, 475 participants
were included in the analyses (age, 77.9 ± 7.0 years; 60.4% females).
Fatty liver index scores were calculated and participants were
stratiﬁed on the basis of NAFLD status. Two hundred and sixteen
participants (45.5%) had FLI scores 60 and were classiﬁed as
having NAFLD. The remaining participants (n ¼ 259, 54.5%) had FLI
scores of <60 and were classiﬁed as non-NAFLD. Participants' de-
mographic characteristics are outlined in Table 1, together with the
results of anthropometric, blood pressure and blood evaluations.
Participants with NAFLDwere younger (77.0 ± 6.6 years) than those
without NAFLD (78.6 ± 7.3 years) and the proportion of females was
lower in the NAFLD group (49.1% vs 70.4%).
As expected, the mean Fatty Liver Index, and the levels of the
four criterion variables, BMI, waist circumference, GGT and TGwere
signiﬁcantly higher in NAFLD participants compared to non-NAFLD
participants (Table 1). Participants with NAFLD had signiﬁcantly
higher body weight, BMI, waist circumference and waist-hip ratio
than non-NAFLD. When the NAFLD and non-NAFLD groups were
stratiﬁed by gender it was found that the mean waist circumfer-
ences of all four subgroups were above the National Heart Foun-
dation reference cut-offs for increased chronic disease risk. The
elevations were more pronounced in females. The mean waist cir-
cumferences for NAFLD females and non-NAFLD females were
31.9% and 8.3% above the reference cutoff of 80 cm, whereas the
mean waist circumference of NAFLD males and non-NAFLD males
were 18.1% and 0.04% above the cutoff of 94 cm [34,37]. Participants
with NAFLD also had signiﬁcantly higher systolic and diastolic
blood pressures, fasting glucose, insulin, ALT and CRP, and signiﬁ-
cantly lower HDL and LDL, compared to those without NAFLD.
Similar differences were observed between NAFLD and non-NAFLD
participants when the male and female subgroups were analysed
separately; although some differences were no longer statistically
signiﬁcant.
3.1. Nutrient intake of study participants
Participants' nutrient intakes are summarised in Table 2. No
signiﬁcant differences in energy, carbohydrate or protein intake
were detected between participants with NAFLD and those without
NAFLD. Total fat, polyunsaturated fatty acid (PUFA) and mono-
unsaturated fatty acid (MUFA) intake were lower in participants
with NAFLD, but only the differences in PUFA intake observed in
the-all participant and female-only comparisons were statistically
signiﬁcant. Alcohol intake was higher in participants with NAFLD
than those without NAFLD (5.4 ± 6.3 g/d versus 4.2 ± 5.7 g/d), and
higher amongmen compared towomen regardless of NAFLD status
(p < 0.05).
3.2. Erythrocyte membrane fatty acid compositions
The fatty acid composition of erythrocyte membranes is pre-
sented in Table 3. Erythrocyte membrane concentrations of pal-
mitic acid (16:0) and total saturated fatty acids were signiﬁcantly
reduced, and palmitoleic acid (16:1n-7) signiﬁcantly increased, in
NAFLD compared to non-NAFLD participants. Similar differences
were evident when participants were stratiﬁed on gender and then
NAFLD status, however, with the exception of the higher palmito-
leic acid content, these differences failed to achieve statistical sig-
niﬁcance. Linoleic acid (18:2n-6) and a-linolenic acid (18:3n-6)
were the only n-6PUFA found to be signiﬁcantly different between
NAFLD and non-NAFLD participants (Table 3). EPA (20:5n-3) was
Table 1
Demographic, anthropometric, blood pressure and blood analyses measures for participants grouped by gender and NAFLD status.a
All participants Males Females
Non-NAFLD (n ¼ 259) NAFLDb (n ¼ 216) Non-NAFLD (n ¼ 78) NAFLD (n ¼ 110) Non-NAFLD (n ¼ 181) NAFLD (n ¼ 106)
Age (yrs) 78.6 ± 7.3 77.0 ± 6.6* 78.7 ± 7.2 76.7 ± 6.3 78.6 ± 7.4 77.4 ± 6.8
Anthropometric measurements, blood pressure and pulse
Height (m) 1.6 ± 0.1 1.6 ± 0.1*** 1.7 ± 0.1 1.7 ± 0.1* 1.6 ± 0.1 1.6 ± 0.1
Weight (kg) 65.5 ± 10.0 86.4 ± 12.5*** 71.4 ± 9.4 90.6 ± 12.4*** 62.9 ± 9.1 81.9 ± 11.0***
BMI (kg/mb) 25.4 ± 3.1 32.0 ± 4.0*** 25.0 ± 2.6 30.8 ± 3.4*** 25.6 ± 3.3 33.3 ± 4.2***
Waist (cm) 89.0 ± 8.8 108.3 ± 9.6*** 94.4 ± 8.2 111.0 ± 9.1*** 86.6 ± 8.1 105.5 ± 9.3***
Hip (cm) 103.2 ± 7.8 115.5 ± 9.1*** 101.8 ± 5.7 111.7 ± 6.7*** 103.7 ± 8.5 119.4 ± 9.5***
Waist/Hip Ratio 0.86 ± 0.07 0.94 ± 0.08*** 0.93 ± 0.07 0.99 ± 0.06*** 0.84 ± 0.06 0.88 ± 0.05***
SBP (mmHg) 144.9 ± 21.1 151.2 ± 19.3** 146.0 ± 22.1 154.7 ± 18.4** 144.4 ± 20.7 147.6 ± 19.6
DBP (mmHg) 72.8 ± 9.4 76.1 ± 10.5*** 73.4 ± 9.3 77.8 ± 10.1** 72.6 ± 9.4 74.5 ± 10.8
Pulse (mmHg) 67.5 ± 10.5 67.8 ± 11.8 64.3 ± 9.7 66.4 ± 12.7 68.9 ± 10.5 69.3 ± 10.7
Glycaemic Indices
Glucose (mmol/L) 5.3 ± 0.8 5.9 ± 1.2*** 5.4 ± 0.8 6.1 ± 1.3** 5.2 ± 0.7 5.8 ± 1.1***
Insulin (mIU/L) 5.9 ± 3.7 10.8 ± 7.0*** 5.8 ± 3.5 9.9 ± 6.5*** 5.9 ± 3.7 11.8 ± 7.4***
Liver Function Tests
GGT (U/L) 26.7 ± 14.0 45.0 ± 43.9*** 26.6 ± 12.7 47.3 ± 50.2*** 26.7 ± 14.5 42.6 ± 36.2***
ALT (U/L) 20.2 ± 9.1 24.0 ± 11.4*** 20.6 ± 7.8 25.7 ± 11.9** 20.1 ± 9.6 22.2 ± 10.5
AST (U/L) 19.4 ± 6.3 19.4 ± 8.0 18.8 ± 6.0 19.7 ± 7.9 19.6 ± 6.4 19.1 ± 8.1
CRP (mg/L) 2.7 ± 3.2 4.0 ± 5.4** 2.5 ± 2.9 3.3 ± 4.7 2.8 ± 3.3 4.8 ± 6.0**
Lipids
Cholesterol (mmol/L) 4.6 ± 1.1 4.4 ± 1.0 4.1 ± 0.9 4.2 ± 0.9 4.8 ± 1.0 4.7 ± 1.1
TG (mmol/L) 1.1 ± 0.4 1.7 ± 0.8*** 1.0 ± 0.4 1.6 ± 0.8*** 1.1 ± 0.4 1.7 ± 0.8***
HDL (mmol/L) 1.6 ± 0.4 1.3 ± 0.4*** 1.4 ± 0.4 1.2 ± 0.3** 1.7 ± 0.4 1.4 ± 0.4***
LDL (mmol/L) 2.5 ± 0.9 2.3 ± 0.9* 2.3 ± 0.9 2.2 ± 0.8 2.6 ± 0.9 2.4 ± 1.0
Fatty Liver Index 31.6 ± 16.6 80.8 ± 11.1*** 34.3 ± 15.3 80.3 ± 11.1*** 30.5 ± 17.0 81.3 ± 11.1***
*Statistically signiﬁcant at p < 0.05; ** Statistically signiﬁcant at p < 0.01; *** Statistically signiﬁcant at p < 0.001.
a Data presented as Mean ± SD. Group differences between NAFLD and non-NAFLD participants were assessed using independent samples t-tests (2-tailed).
b Participants were deﬁned as having NAFLD if they had a FLI score 60 [21]. FLI score includes BMI, waist circumference, TG and GGT [21].
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after adjusting for gender, no signiﬁcant differences in EPA levels
were found. DHA (22:6n-3), total n-3PUFA, and O3I were signiﬁ-
cantly lower in participants with NAFLD compared to thosewithout
NAFLD in both the all participants and female-only subgroups, but
no differences were noted in males (Table 3).
3.3. Correlation analyses
Bivariate correlation analyses showed that O3I was negatively
associated with weight, BMI, waist circumference, waist:hip ratio,
glucose, and TG, and positively correlated with HDL in all partici-
pants. Gender speciﬁc differences were evident (Table 4). In the
female-only group, O3I was inversely associated with weight, BMI,
waist circumference, hip circumference, TG, and CRP and positively
associated with AST, ALT and HDL. These associations did not exist
in males. O3I and FLI were inversely associated in all participants,
however, stratiﬁcation on gender revealed that this relationshipTable 2
Nutrient intakes of participants grouped by gender and NAFLD status.a
All participants Males
Non-NAFLD (n ¼ 259) NAFLDb (n ¼ 216) Non-NAFLD
Energy (kJ) 7840.9 ± 3164.2 7877.7 ± 2926.3 7833.1 ± 252
Protein (g) 87.6 ± 38.5 88.1 ± 33.4 86.7 ± 31.
Total Fat (g) 67.6 ± 34.2 64.8 ± 29.7 66.6 ± 28.
SFA (g) 22.9 ± 11.9 22.8 ± 11.3 22.6 ± 10.
MUFA (g) 26.2 ± 14.0 25.3 ± 13.0 26.0 ± 12.
PUFA (g) 11.9 ± 9.9 10.2 ± 6.1* 11.3 ± 7.1
Carbohydrate (g) 207.8 ± 92.2 213.5 ± 91.0 208.5 ± 72.
Fibre (g) 30.9 ± 15.4 30.9 ± 14.5 29.9 ± 12.
Cholesterol (mg) 233.9 ± 131.1 236.8 ± 112.9 224.8 ± 106
Alcohol (g) 4.2 ± 5.7 5.4 ± 6.3* 5.7 ± 6.6
* Statistically signiﬁcant at p < 0.05.
a Data presented as Mean ± SD. Group differences between NAFLD and non-NAFLD pa
b Participants were deﬁned as having NAFLD if they had a FLI score 60 [21]. FLI scorwas also speciﬁc to females. O3I was also inversely associated with
total MUFA and total n-6PUFA, and positively associated with total
n-3PUFA, regardless of gender.
3.4. O3I and NAFLD
The prevalence of NAFLD among participants sub-grouped into
quartiles on the basis of their O3I scores is presented in Table 5.
When NAFLD prevalence was compared across the four quartiles,
the odds of having NAFLD was lower in participants in the highest
O3I quartile (0.65) compared to those in the lowest O3I quartile
(1.0; P-trend¼ 0.018). This trend was also apparent in females, with
the odds ratio decreasing from 1.0 (quartile 1) to 0.55 (quartile 4; P-
trend ¼ 0.025), but not in males, where the odds ratios for the ﬁrst
and fourth quartiles were 1.00 and 1.09, respectively.
It was noted that the prevalence and risk of NAFLD for the lower
two O3I quartiles were comparable in magnitude (Quartile 1:
49.6%, OR ¼ 1.00; Quartile 2: 55.1%, OR ¼ 1.25) as was theFemales
(n ¼ 78) NAFLD (n ¼ 110) Non-NAFLD (n ¼ 181) NAFLD (n ¼ 106)
1.3 8107.1 ± 3217.4 7844.3 ± 3410.5 7639.7 ± 2583.7
6 90.3 ± 35.2 88.0 ± 41.2 85.8 ± 31.4
8 66.0 ± 31.7 68.0 ± 36.3 63.5 ± 27.5
4 23.1 ± 11.9 23.0 ± 12.5 22.5 ± 10.7
3 26.0 ± 13.9 26.2 ± 14.7 24.6 ± 12.1
10.3 ± 6.6 12.2 ± 10.9 10.0 ± 5.5*
2 219.6 ± 100.4 207.5 ± 99.8 207.3 ± 80.2
1 31.4 ± 15.1 31.4 ± 16.7 30.4 ± 13.9
.8 243.8 ± 121.4 237.9 ± 140.4 229.5 ± 103.4
7.0 ± 6.8 3.5 ± 5.2 3.8 ± 5.2
rticipants were assessed using independent samples t-tests (2-tailed).
e includes BMI, waist circumference, TG and GGT [21].
Table 3
Erythrocyte membrane fatty acid composition of participants grouped by gender and NAFLD status.a
Fatty acid (%)
All participants Males Females
Non-NAFLD (n ¼ 259) NAFLDb (n ¼ 216) Non-NAFLD (n ¼ 78) NAFLD (n ¼ 110) Non-NAFLD (n ¼ 181) NAFLD (n ¼ 106)
SFA
16:0 22.9 ± 1.1 22.7 ± 1.3* 22.9 ± 1.1 22.7 ± 1.4 22.9 ± 1.1 22.6 ± 1.3
18:0 18.6 ± 1.2 18.4 ± 1.6 18.7 ± 1.4 18.3 ± 1.6 18.6 ± 1.1 18.5 ± 1.5
20:0 0.6 ± 0.1 0.6 ± 0.4 0.6 ± 0.1 0.6 ± 0.6 0.6 ± 0.1 0.6 ± 0.1
Total SFA 42.2 ± 1.8 41.7 ± 2.4* 42.2 ± 2.1 41.7 ± 2.5 42.1 ± 1.7 41.8 ± 2.4
MUFA
16:1n-7 0.5 ± 0.2 0.6 ± 0.3*** 0.5 ± 0.2 0.6 ± 0.3* 0.6 ± 0.2 0.7 ± 0.4***
18:1n-7 1.8 ± 0.3 1.7 ± 0.4 1.8 ± 0.3 1.7 ± 0.4* 1.8 ± 0.3 1.8 ± 0.4
Total MUFA 2.3 ± 0.5 2.3 ± 0.6 2.2 ± 0.5 2.2 ± 0.6 2.3 ± 0.5 2.5 ± 0.7
n-6 PUFA
18:2n-6 9.0 ± 1.4 8.5 ± 1.5** 9.2 ± 1.3 8.7 ± 1.5* 8.9 ± 1.4 8.4 ± 1.5**
18:3n-6 0.2 ± 0.2 0.2 ± 0.2* 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2*
20:2n-6 0.3 ± 0.1 0.3 ± 0.3 0.3 ± 0.1 0.3 ± 0.3 0.3 ± 0.1 0.3 ± 0.1
20:3n-6 1.5 ± 1.2 1.5 ± 1.1 1.5 ± 1.2 1.6 ± 1.2 1.4 ± 1.1 1.4 ± 1.1
20:4n-6 16.7 ± 2.5 16.9 ± 2.4 16.9 ± 2.6 16.9 ± 2.4 16.6 ± 2.5 16.8 ± 2.4
Total n-6PUFA 27.7 ± 2.6 27.5 ± 2.5 28.1 ± 2.7 27.7 ± 2.5 27.5 ± 2.6 27.2 ± 2.6
n-3 PUFA
18:3n-3 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
20:5n-3 1.7 ± 1.0 1.6 ± 0.9* 1.5 ± 0.9 1.5 ± 0.8 1.8 ± 1.0 1.7 ± 0.9
22:5n-3 3.6 ± 0.7 3.5 ± 0.7 3.6 ± 0.7 3.5 ± 0.6 3.6 ± 0.7 3.5 ± 0.8
22:6n-3 6.9 ± 1.4 6.6 ± 1.3** 6.5 ± 1.5 6.5 ± 1.4 7.1 ± 1.4 6.6 ± 1.3**
Total n-3PUFA 12.5 ± 2.6 11.9 ± 2.4** 11.9 ± 2.5 11.7 ± 2.4 12.7 ± 2.6 12.0 ± 2.4*
Omega-3 Indexc 8.6 ± 2.2 8.1 ± 2.0** 8.0 ± 2.1 8.0 ± 2.0 8.9 ± 2.2 8.3 ± 2.0*
* Statistically signiﬁcant at p < 0.05; ** Statistically signiﬁcant at p < 0.01; *** Statistically signiﬁcant at p < 0.001.
a Data presented as Mean ± SD. Group differences between NAFLD and non-NAFLD participants were assessed using independent samples t-tests (2-tailed).
b Participants were deﬁned as having NAFLD if they had a FLI score 60 [21]. FLI score includes BMI, waist circumference, TG and GGT [21].
c O3I: Omega-3 index ¼ erythrocyte EPA% þ DPA% of total erythrocyte fatty acids [50].
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(Quartile 3: 38.3%, OR ¼ 0.63; Quartile 4: 39.0%, OR ¼ 0.65). When
the prevalence of NAFLD among participants in the lower two
quartiles was combined (n ¼ 124, 52.3%, OR ¼ 1.00) and compared
to the prevalence of NAFLD among participants in the upper two
quartiles (n ¼ 92, 38.7%, OR ¼ 0.57), a signiﬁcant reduction in the
risk of NAFLD was observed in the quartiles with the higher O3I
scores (c2 ¼ 8.94, p ¼ 0.003).Table 4
Correlation analyses of the relationship between omega-3 fatty acids and age, anthrop
grouped by gender.a
All participants (n ¼ 475)
Omega-3 indexb
Height (m) 0.058
Weight (kg) 0.120**
BMI (kg/m2) 0.103*
Waist (cm) 0.139**
Hip (cm) 0.057
Waist:hip ratio 0.148**
Glucose (mmol/L) 0.096*
Insulin (mIU/L) 0.042
GGT (U/L) 0.068
AST (U/L) 0.082
ALT (U/L) 0.083
Cholesterol (mmol/L) 0.048
TG (mmol/L) 0.229***
LDL (mmol/L) 0.056
HDL (mmol/L) 0.160***
CRP (mg/L) 0.081
Total SFA 0.031
Total MUFA 0.162***
Total n-6PUFA 0.652***
Total n-3PUFA 0.971***
Fatty Liver Index 0.165***
Participants were deﬁned as having NAFLD if they had a FLI score 60 [21]. FLI score in
* Statistically signiﬁcant at p < 0.05; ** Statistically signiﬁcant at p < 0.01; *** Statisticall
a Values are correlation coefﬁcients (r) calculated using Pearson product-moment cor
b O3I: Omega-3 index ¼ erythrocyte EPA% þ DPA% of total erythrocyte fatty acids [503.5. Hierarchical multiple linear regression analysis
The results of the hierarchical regression analysis of the rela-
tionship between the fatty liver index, O3I scores and other clini-
cally relevant variables are outlined in Table 6. Age and genderwere
signiﬁcantly associated with FLI (Model 1, R¼ 0.239, p < 0.001) and
accounted for 5.7% of variation in FLI scores (DR2 ¼ 0.057,
p < 0.001). The addition of fasting glucose, insulin, HDL and CRP atometric measures, and blood biochemistry for all participants and for participants
Males (n ¼ 188) Females (n ¼ 287)
0.052 0.107
0.037 0.126*
0.023 0.171**
0.024 0.149*
0.030 0.118*
0.012 0.104
0.018 0.107
0.045 0.093
0.065 0.045
0.053 0.166**
0.019 0.165**
0.080 0.046
0.115 0.311***
0.003 0.052
0.050 0.191**
0.048 0.117*
0.083 0.000
0.165* 0.195**
0.602*** 0.674***
0.927*** 0.970***
0.013 0.206***
cludes BMI, waist circumference, TG and GGT [21].
y signiﬁcant at p < 0.001.
relation analyses.
].
Table 5
The prevalence of NAFLD in the lowest and highest quartiles of omega-3 index scores, and the prevalence of NAFLD within the male and female subgroups for those quartiles.a
O3Ib
quartiles
All participants Males Females
Number of
people without
NAFLD (n ¼ 259)
Number of
people with
NAFLD
(n ¼ 216)
OR (95% CI) Number of
people without
NAFLD (n ¼ 78)
Number of
people with
NAFLD
(n ¼ 110)
OR (95% CI) Number of
people without
NAFLD (n ¼ 181)
Number of
people with
NAFLD
(n ¼ 106)
OR (95% CI)
1 60 (50.4%) 59 (49.6%) 1.00 (reference) 25 (43.1%) 33 (56.9%) 1.00 (reference) 35 (57.4%) 26 (42.6%) 1.00 (reference)
2 53 (44.9%) 65 (55.1%) 1.25 (0.75e2.08) 20 (35.7%) 36 (64.3%) 1.36 (0.64e2.90) 33 (53.2%) 29 (46.8%) 1.18 (0.58e2.41)
3 74 (61.7%) 46 (38.3%) 0.63 (0.38e1.06) 17 (48.6%) 18 (51.4%) 0.80 (0.35e1.86) 57 (67.1%) 28 (32.9%) 0.66 (0.34e1.31)
4 72 (61.0%) 46 (39.0%) 0.65 (0.39e1.09) 16 (41.0%) 23 (59.0%) 1.09 (0.48e2.48) 56 (70.9%) 23 (29.1%) 0.55 (0.27e1.11)
P-trend <0.05 ns <0.05
Participants were deﬁned as having NAFLD if they had a FLI score 60 [21]. FLI score includes BMI, waist circumference, TG and GGT [21]. Odds Ratio (OR) calculated using
lowest quartile as reference. Trends in proportion are assessed using linear-by-linear association. ns, not statistically signiﬁcant at p < 0.05.
a Quartile ranges were determined using the data from all participants and were as follows [1]: 4.16%e6.84% [2]; 6.85%e7.99% [3]; 8.00%e9.78% [4]; 9.80%e14.81%.
b O3I: Omega-3 index ¼ erythrocyte EPA% þ DPA% of total erythrocyte fatty acids [50].
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the variation in FLI (Model 2: R ¼ 0.618, p < 0.001; DR2 ¼ 0.325,
p < 0.001). The inclusion of O3I at the ﬁnal block of the analysis also
contributed signiﬁcantly to the prediction of FLI (DR2 ¼ 0.005,
p < 0.05), although its individual contribution to the predictive
power was small. When all seven independent variables were
included in the model, with the exception of age, all contributed
uniquely to the multivariate correlation (Table 6).Table 6
Hierarchical multiple regression analyses of the relationship between FLI and
Omega-3 index (O3I) in all participants (n ¼ 475) after controlling for potentially
confounders.a
All participants
Block 1 Model
Model Statistics R ¼ 0.239, R2 ¼ 0.057, Adj.
R2 ¼ 0.053, F(2,469) ¼ 14.145,
p < 0.001
R2D Statistics R2D ¼ 0.057, F(2,469) ¼ 14.145,
p < 0.001
Variables b p
Age (yrs) 0.119 0.008
Gender 0.202 0.000
Block 2 Model
Model Statistics R ¼ 0.618, R2 ¼ 0.381, Adj.
R2 ¼ 0.373, F(6,465) ¼ 47.791,
p < 0.001
R2D Statistics R2D ¼ 0.325, F(4,465) ¼ 60.995,
p < 0.001
Variables b p
Age (yrs) 0.050 0.172
Gender 0.098 0.015
F. Glucose (mmol/L) 0.179 0.000
Insulin (mIU/L) 0.360 0.000
HDL (mmol/L) 0.211 0.000
CRP (mg/L) 0.128 0.001
Block 3 Model
Model Statistics R ¼ 0.622, R2 ¼ 0.387, Adj.
R2 ¼ 0.377, F(7,464) ¼ 41.783,
p < 0.001
R2D Statistics R2D ¼ 0.005, F(1,464) ¼ 3.927,
p < 0.05
Variables b p
Age (yrs) 0.048 0.190
Gender 0.089 0.028
F. Glucose (mmol/L) 0.175 0.000
Insulin (mIU/L) 0.361 0.000
HDL (mmol/L) 0.203 0.000
CRP (mg/L) 0.122 0.001
O3I 0.074 0.048
* Statistically signiﬁcant at p < 0.05; ** Statistically signiﬁcant at p < 0.01; *** Sta-
tistically signiﬁcant at p < 0.001.
a O3I: Omega-3 index ¼ erythrocyte EPA% þ DPA% of total erythrocyte fatty acids
[50]. A three block hierarchical multiple regression analysis was conducted.4. Discussion
This is the ﬁrst study to investigate an association between
O3I and NAFLD amongst older adults (65 years) using an
objective measure of long-term n-3PUFA status. The study found
an inverse association between O3I and NAFLD in female but not
male participants, suggesting that sex differences may be an
important consideration when evaluating the efﬁcacy of n-
3PUFA in the prevention of NAFLD. Previous research has drawn
inconsistent conclusions on correlations between n-3PUFA levels
and NAFLD. A recent systematic review by Parker et al. [3] reported
that n-3PUFA supplementation was effective in the reduction of
hepatic steatosis in adults aged >18 years, with one study [38]
reporting a reversal of hepatic steatosis to normal liver function
in 33.4% of participants. Despite some design ﬂaws (randomization
and blinding) in the reviewed studies, the ﬁndings indicated a
potential role for n-3PUFA in the prevention and treatment of
NAFLD.
To date, the majority of intervention studies have examined the
effect of n-3PUFA supplementation on NAFLD in mixed-gender
participant groups [3,19], with the exception of a few studies that
were conducted speciﬁcally in women and that showed a signiﬁ-
cant reduction in hepatic steatosis [39,40]. A recent study demon-
strated that O3I was associated with liver fat concentration [38,39].
However, when O3I was included in a multivariate analysis, it did
not signiﬁcantly improve the overall capacity of demographic,
anthropometric and blood markers to predict NAFLD [38,39,41]. In
this study, 70% of the participants were men, which may have
attenuated the correlation observed. The use of mixed gender
groups may potentially explain some of the inconsistencies found
in reported outcomes and indicates the need for further sex and age
speciﬁc intervention studies to more clearly delineate the role of n-
3PUFA in NAFLD.
The prevalence of NAFLD in the current study population of
older adults aged 65 years and over was 45% compared with 3% in
children [42], 5e39% in adults aged 18e39 years [5] and 40% in
adults aged 50 years and older [5]. Older populations may have an
increased risk of developing NAFLD, due to the increased preva-
lence of co-morbidities and metabolic abnormalities in this age
group, as well as decreased levels of physical activity [43]. The
increased prevalence of NAFLD in this population emphasizes the
need for the development of strategies to prevent and treat NAFLD
in elderly populations.
BMI, waist circumference, TG and GGT were also individually
negatively correlated with O3I, and the prevalence of NAFLD was
higher in participants with lower O3I scores.
In our study, 69% of participants with NAFLD were classiﬁed as
obese (BMI 30.0 kg/m2). Recent research investigating the
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inconsistent ﬁndings. A review by Buckley and Howe, 2009 [44]
reported reductions in adiposity with increasing n-3PUFA levels,
however the majority of the studies discussed were short-term
and conducted in conjunction with energy-restricted dietary -
interventions. In contrast, a double blind randomized controlled
trial (RCT) conducted in young adults aged 20e35 years reported
no signiﬁcant alterations in anthropometric measurements
with increasing n-3PUFA supplementation [45]. In the current
study, an inverse association between O3I and BMI was found
in females alone. This ﬁnding further supports the need for
gender speciﬁc intervention trials. Buckley and Howe discussed
a number of possible mechanisms by which n-3PUFAs may
affect weight/BMI [44], including n-3PUFA mediated alterations in
gene transcription factors that play a role in hepatic lipid produc-
tion and maintenance, in particular peroxisome proliferator-
activated receptor a (PPARa) and sterol regulatory element-
binding protein 1 (SREBP-1) [7]. Individuals with obesity have
been shown to have a lower dietary intake of n-3PUFA. As n-3PUFA
are known to regulate the expression of hepatic gene transcription
factors such as PPARa and SREBP-1 [7,13] resulting in the induction
of hepatic fatty acid oxidation and inhibition of fatty acid synthesis,
reduced n-3PUFA levels may predispose obese individuals to
NAFLD.
Previous studies have reported that high doses of n-3PUFA
supplementation signiﬁcantly lower serum triglycerides [18],
another component of the FLI. These ﬁndings are supported by
more recent evidence, with a 2011 RCT conducted in men and post-
menopausal women, reporting a signiﬁcant reduction in serum
triglycerides with a higher dose (3.4 g/day) of n-3PUFA supple-
mentation [46]. In our study, however, females alone showed an
inverse association between O3I and TG.
Similar to a recent animal study investigating the effects of
n-3PUFA and n-6PUFA on GGT [47], we found no association be-
tween O3I and GGT. In the former study, Ketsa and Marchenko
found that GGT and ALT levels were not affected by n-3PUFA sup-
plementation, but reported a reduction in AST [47]. In the present
study, in females, both AST and ALT levels were positively corre-
lated with O3I.
The O3I values obtained in our study population are relatively
high in comparison to existing O3I studies [48]. This elevation may
result from the methodology used to analyse the erythrocyte
membrane fatty acids, and/or the age of the study participants
(65e95 years) [49].
The gold standard for diagnosis of NAFLD is liver biopsy, but it is
not frequently performed due to its invasive nature and low
acceptance rate. Ultrasonography is more commonly used to detect
NAFLD because it is non-invasive, sensitive, low-cost and easy to
perform. In the present study, we used FLI, a validated tool to
predict NAFLD, however, the lack of histological ﬁndings or a direct
measure of NAFLD remains a drawback of our investigation.
Strengths of this study include the relatively large sample size,
and consequent generalizability to the aged population, and the use
of a long-term objective biomarker of O3I that allowed a more
accurate measure of long-term n-3PUFA status. Additional limita-
tions include cross sectional design, self-reported dietary intake
and lack of separation of PUFA intake into n-3PUFA and n-6PUFA.
NAFLD is deﬁned as the hepatic expression of the metabolic syn-
drome. Medications used to treat metabolic syndrome may there-
fore be considered as potential confounders to NAFLD research. In
the current study, a small number of participants were taking
medications for type 2 diabetes mellitus, hypertension, lowering
lipids and weight loss. These medications may have altered NAFLD
expression by inﬂuencing one or more of the four variables incor-
porated into the calculation of FLI.5. Conclusion
In conclusion, we found a signiﬁcant inverse association be-
tween erythrocyte O3I and FLI scores in older adults, supporting a
relationship between O3I and NAFLD. The association between O3I
and FLI was gender-speciﬁc, being only apparent in females. Sex-
based RCT's using objective measures of NAFLD should be con-
ducted to validate and further investigate these ﬁndings.
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